'On consolidated basis
Quarter ended December 2025 compared with Quarter ended December 2024.
Net sales (including other operating income) of Zydus Lifesciences has increased 30.28% to Rs 6864.5 crore. Operating profit margin has jumped from 26.33% to 26.46%, leading to 30.90% rise in operating profit to Rs 1,816.40 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 19.43% to 17.14%. Purchase of finished goods cost rose from 10.81% to 12.00%. Employee cost decreased from 17.91% to 16.06%. Other expenses rose from 25.58% to 29.20%.
Other income rose 93.74% to Rs 111.4 crore. PBIDT rose 33.40% to Rs 1927.8 crore. Provision for interest rose 305.94% to Rs 129.9 crore.
PBDT rose 27.23% to Rs 1797.9 crore. Provision for depreciation rose 57.03% to Rs 359.6 crore.
Profit before tax gr...
Pleaselogin & subscribe to view the full report.
More Reports
|
|